ArticleJournal of the American College of Cardiology2026
Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.
Article in Journal of the American College of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond sex determination: the Y chromosome in male cancers.Nature reviews. Cancer · 2026Review
- Direct probabilistic quantification of mosaic loss of chromosome Y from sequencing data.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundLoss of the Y chromosome (LOY) from a percentage of circulating leukocytes is common in older men and is associated with cardiovascular risk. However, most studies have involved men with preexisting disease, not healthy men followed prospectively.
objectivesThis study sought to investigate the association between LOY and risk of incident major adverse cardiovascular events (MACEs), including myocardial infarction (MI) and ischemic stroke.
methodsThis study included 5,131 men aged ≥ 65 years from the ASPREE (ASPirin in Reducing Events in the Elderly) trial with no prior cardiovascular disease at baseline. LOY percentage was measured in peripheral blood using microarrays and the log-R-ratio method. MACEs, including MI and ischemic stroke, were collected during the trial and subsequent observational follow-up. Cox regression assessed associations of LOY as a continuous (per SD) and categorical (decile-based) variable. Deciles 1 through 6 (reference) represented no LOY, deciles 7 through 9 moderate, and decile 10 substantial.
resultsOver a median of 8.4 years of follow-up, 9.8% men (n = 505) experienced MACEs, with 5% (n = 256) MI and 4% (n = 207) ischemic stroke. In the fully adjusted model, each SD increase in LOY was associated with 14% higher MI risk (HR per SD: 1.14; 95% CI: 1.02-1.28). Men with substantial LOY (decile 10) had 68% higher MI risk vs men without LOY (HR: 1.68; 95% CI: 1.16-2.54). No associations were observed for ischemic stroke. Results were robust to sensitivity analyses. In 191,340 men aged 40 to 70 years from the UK Biobank, LOY was also associated with MI (HR per SD: 1.03; 95% CI: 1.01-1.06).
conclusionsLOY is associated with increased MI risk, but not stroke, in older men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.